NCT04453124

Brief Summary

In a search for accessible treatment options, plant medicines used by different communities in Papua New Guinea have been tested to identify the sap of the tree, Ficus septica, as a promising antibacterial agent in vitro. This is an open label clinical trial using an interventional approach, to compare the effect of the antiseptic plant sap and standard topical antiseptic, on the rate of wound development prevention and bacterial growth. If shown to be effective, this readily available plant medicine can provide a zero-cost treatment option in remote areas of PNG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Nov 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2019

Completed
21 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 22, 2019

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 25, 2019

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

June 21, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

July 1, 2020

Completed
Last Updated

September 3, 2020

Status Verified

September 1, 2020

Enrollment Period

21 days

First QC Date

June 21, 2020

Last Update Submit

September 1, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of participants with Clinical Healing in each arm

    surface reduction by more than 50%

    21 days

  • Number of participants with Clinical Healing in each arm

    Ulcer healing determined by a professional dermatologist, described as as: appearance of granulation tissue, healed borders, dry ulcer, no exudation.

    21 days

Secondary Outcomes (1)

  • Changes in wound microbiology

    21 days

Study Arms (3)

Soap and Water

NO INTERVENTION

Standard of care using soap and water

Ficus Septica Sap

EXPERIMENTAL

Ficus Septica Sap, topical cream, 50ul, daily, for 2 days

Biological: Topical antiseptic treatment

Chlorhexidine (Topical)

ACTIVE COMPARATOR

Chlorhexidine, topical solution, 50ul, daily, for 2 days

Biological: Topical antiseptic treatment

Interventions

Prevent the development of bacterial cutaneous ulcers by applying antiseptic sap from Ficus septica tree on small wounds.

Chlorhexidine (Topical)Ficus Septica Sap

Eligibility Criteria

Age5 Years - 15 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • children aged 5 to 15 with parental consent and with one or more skin breaks of any nature (i.e. Skin cuts, scratch, scrapes or abrasion and mosquito bites) that are less than 1cm in major diameter. Written informed consent by parent or guardian will be required before enrolment.

You may not qualify if:

  • All participants who have received medical treatment for skin ulcers up to 2 months prior to recruitment (azithromycin, amoxicillin, benzathine penicillin, etc.).
  • Patients who require antibiotic treatment for another condition not-related to the study.
  • Known history of hypersensitivity, allergic or adverse reaction to the study product.
  • Patients presenting cutaneous ulcer more than 1cm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Lihir Medical Centre

Londolovit, New Ireland Province, 034, Papua New Guinea

Location

University of Papua New Guinea

Port Moresby, Papua New Guinea

Location

MeSH Terms

Conditions

YawsSkin Ulcer

Condition Hierarchy (Ancestors)

Treponemal InfectionsSpirochaetales InfectionsGram-Negative Bacterial InfectionsBacterial InfectionsBacterial Infections and MycosesInfectionsSkin Diseases, BacterialSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Assessor of healing outcomes through pictures will not know the arm of origen of the pictures .
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr. Oriol Mitja

Study Record Dates

First Submitted

June 21, 2020

First Posted

July 1, 2020

Study Start

November 1, 2019

Primary Completion

November 22, 2019

Study Completion

November 25, 2019

Last Updated

September 3, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will share

All individual variables will be available through direct contact with corresponding author

Shared Documents
STUDY PROTOCOL
Time Frame
After publication of data for 1 year

Locations